Aims & Scope
Tumor Biology is a peer reviewed, international journal providing an open access forum for experimental and clinical cancer research. It covers all aspects of tumor markers, molecular biomarkers, tumor targeting, and mechanisms of tumor development and progression.
Specific topics of interest include, but are not limited to:
• Pathway analyses
• Non-coding RNAs
• Circulating tumor cells
• Liquid biopsies
• Cancer stem cells
• Tumor immunology and immunotherapy
• Tumor microenvironment
• Targeted therapies
• Therapy resistance
• Cancer genetics
• Cancer risk screening.
Studies in other areas of basic, clinical, and translational cancer research are also considered in order to promote connections and discoveries across different disciplines.
The journal publishes original articles, reviews, commentaries, and guidelines on tumor marker use. All submissions are subject to rigorous peer review and are selected on the basis of whether the research is sound and deserves publication.
Tumor Biology is the official journal of the International Society of Oncology and BioMarkers (ISOBM).
Magdalena Chechlinska, PhD, Dr Habil
Maria Sklodowska-Curie National Research Institute of Oncology
Northeastern University, Boston
University of Bonn, Bonn
Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw
University Hospital Basel, Basel
University of the Basque Country, Leioa
Hadassah Medical Center, Jerusalem
University of Navarra, Pamplona
University of Nottingham, Nottingham
Chi Hin Cho
The Chinese University of Hong Kong, Hong Kong
Jose Luis Costa
University of Porto, Porto
Mount Sinai Hospital, Toronto
University College Dublin, Dublin
Umeå Universitet, Umeå
The University of Tokyo, Tokyo
University Health Network & University of Toronto, Toronto
Chien-Feng (Angelo) Li
Chi Mei Medical Center
Leendert H. J. Looijenga
Princess Máxima Center for Pediatric Oncology, Utrecht
University of Pisa, Pisa
University College London
London, United Kingdom
Johanna (Hanny) M.A. Pijnenborg
Radboud University Medical Center, Nijmegen
Huub van Rossum
The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam
Ulf Hakan Stenman
University of Helsinki, Helsinki
Katholieke Universiteit Leuven, Leuven
Cabell's Guide or Directory
Directory of Open Access Journals (DOAJ)
Peer Review Policy
Tumor Biology is a peer-reviewed journal. Articles submitted to the journal undergo a single blind peer review process. This means that the identity of the authors is known to the reviewers but the identity of the reviewers is not communicated to the authors. Please visit our reviewer guidelines for further information about how to conduct a review.
All submitted manuscripts are subjected to initial appraisal by the Editor-in-Chief and, if found suitable for further consideration, to rigorous peer review by independent, anonymous expert referees. Reasons to reject a paper in the pre-screening process could for example be that the work does not fall within the aims and scope, the writing is of poor quality, the instructions to authors were not followed or the presented work is not novel.
Papers deemed suitable to be reviewed will be assigned to a handling editor. The handling editor will then invite reviewers to comment on the work. Editors and reviewers are asked to excuse themselves from reviewing a submission if a conflict makes them unable to make an impartial scientific judgment or evaluation. Conflicts of interest include but are not limited to: collaboration with the authors in the past three years; any professional or financial affiliations that may be perceived as a conflict of interest; a history of personal differences with the author(s).
As a standard policy, decisions are based on two reviews. The Editor-in-Chief strives to ensure a typical turnaround time of 3 months.
Reviewers are asked to judge a paper on at least:
- Significance to field
- Relevance to journal
- Data analysis
- Literature review
- Writing style/clarity
Based on the received reviews the handling editor will propose to the Editor-in-Chief a recommendation:
- Minor revisions required
- Major revisions required
They mean the following:
- The manuscript is suitable for publication, thus no further reviews are requested.
- The authors are required to make moderate changes to their manuscript. The manuscript becomes acceptable for publication if the changes proposed by the reviewers and editors have been addressed satisfactorily. The revised manuscript will be examined by the Editor-in-Chief and possibly sent back to all (or a selection of) reviewers for a second round of reviews. Authors are requested to provide a letter to the reviewers detailing the improvements made for the resubmission.
- The manuscript cannot be accepted for publication in its current form. However, a major revision addressing all issues raised by the reviewers may be acceptable for publication. The revised manuscript will undergo a full second round of review. Authors are requested to provide a letter to the reviewers detailing the improvements made for the resubmission.
- The manuscript is rejected as it is deemed to be out of scope, not relevant, or not meeting the journal’s quality standards in terms of significance, novelty, and/or presentation.
Authors are notified by the Editor-in-Chief, whose decision is final.
Call for Papers: A new special issue on "Lung Cancer Tumor Markers" is planned, with guest editors Stefan Holdenrieder, Michel van den Heuvel, and Huub van Rossum (submission deadline: October 31, 2022). Discover ore on the dedicated webpage here or full details here (opens in new tab as PDF).
New from 2021: Tumor Biology is published by IOS Press as of January 1, 2021 onwards. The first articles were published in April 2021. The journal is published in association with the International Society of Oncology and BioMarkers. Content is published in this open access journal on a rolling basis, in one volume and issue per year.
Recent back issues: All content in Volumes 39 to 42 can be accessed via the Sage journal platform here.
Discover the latest articles published in the journal:
Predictive biomarkers for response to trametinib in non-small cell lung cancer
Gregory M. Botting, Palak R. Parekh, Denise B. Thurber, Marika Boruszczak, William Murphy, Greg P. Bertenshaw
Role of colony-stimulating factor 1 in the neoplastic process of tenosynovial giant cell tumor
John H. Healey, William D. Tap
ErbB4-encoded novel miRNAs act as tumor suppressors by regulating ErbB/PI3K signaling
Bahram M. Soltani, Zahra Ghaemi, Seyed Javad Mowla
HE4 and CA125 serum biomarker monitoring in women with epithelial ovarian cancer
M. Craig Miller, Alexandra Samborski, Alexandra Blackman, Shannon MacLaughlan-David, Amanda Jackson, Geralyn Lambert-Messerlian, Rachel Rowswell-Turner, Richard G. Moore
Induction of alternative NF-κB within TAg-induced basal mammary tumors in activation-resistant inhibitor of κ-B kinase (IKKα) mutant mice
Andrea Sau, Fares Ould-Brahim, David A. Carr, Tianqi Jiang, M.A. Christine Pratt